ライフサイエンスコーパス: hematopoietic growth factor

1 er than the conventional dose used without a hematopoietic growth factor.

2 and IL-3, which is a novel property of this hematopoietic growth factor.

3 oteins is involved in signal transduction of hematopoietic growth factors.

4 ss regulated by a family of lineage specific hematopoietic growth factors.

5 pears to be under the control of an array of hematopoietic growth factors.

6 to expand in liquid cultures in response to hematopoietic growth factors.

7 s myelotoxicity is prevented with the use of hematopoietic growth factors.

8 ere cultured 4 days in serum-free media with hematopoietic growth factors.

9 e, with no patient requiring transfusions or hematopoietic growth factors.

10 kinase, which is activated in blood cells by hematopoietic growth factors.

11 cells (HSC) can be significantly expanded by hematopoietic growth factors.

12 in methylcellulose medium supplemented with hematopoietic growth factors.

13 current evidence on the role of recombinant hematopoietic growth factors.

14 ns only), mycophenolate mofetil, and porcine hematopoietic growth factors.

15 esis was not due to redundancy between these hematopoietic growth factors.

16 whether survivin expression was regulated by hematopoietic growth factors.

17 kinase is stimulated by various stresses and hematopoietic growth factors.

18 human bone marrow cells to exogenously added hematopoietic growth factors.

19 ), the growth of Mo7e cells was dependent on hematopoietic growth factors.

20 gnal transduction events elicited by several hematopoietic growth factors.

21 es, in the presence of suitable cocktails of hematopoietic growth factors.

22 blood stem cells through synergy with other hematopoietic growth factors, 5) expanding progenitor ce

23 It is a hematopoietic growth factor, a cytokine involved in infl

24 HIP(-/-) mice are hyperresponsive to certain hematopoietic growth factors, a phenotype very similar t

25 Most hematopoietic growth factors act selectively as survival

26 Hematopoietic growth factors allow dose escalation of ch

27 ll factor (SCF), a potent comitogen for many hematopoietic growth factors, also synergized with GM-CS

28 The use of hematopoietic growth factors, although well established

29 oral and geographic variations in the use of hematopoietic growth factors among patients receiving ch

30 The contribution of interleukin-3 (IL-3), a hematopoietic growth factor and immunoregulatory cytokin

31 nt of apheresis technology, the discovery of hematopoietic growth factors and small molecule CXCR4 an

32 the molecular cloning and expression of many hematopoietic growth factors and their receptors, as wel

33 ylcellulose cultures in the absence of added hematopoietic growth factors and, at higher frequency, i

34 cyclosporine, mycophenolate mofetil, porcine hematopoietic growth factors, and anti-alphaGal antibody

35 luding: intravenous immunoglobulins, myeloid hematopoietic growth factors, and granulocyte transfusio

36 , pharmacological immunosuppression, porcine hematopoietic growth factors, and immunoadsorption of an

37 gene products of the Wnt family function as hematopoietic growth factors, and that they may exhibit

38 Hematopoietic growth factors are being administered to p

39 s) mobilized with high-dose chemotherapy and hematopoietic growth factors are now widely used to supp

40 Hematopoietic growth factors are used to reverse chemoth

41 er of the tyrosine kinase receptor family of hematopoietic growth factors, are discussed.

42 The use of hematopoietic growth factors as primary prophylaxis may

43 t attempts to ex vivo expand HSPCs have used hematopoietic growth factors but have not achieved clini

44 and differentiation in the absence of added hematopoietic growth factors but that stimulation with c

45 The large majority were dependent on hematopoietic growth factors, but a low frequency of aut

46 lood by a wide variety of stimuli, including hematopoietic growth factors, chemotherapy, and chemokin

47 otics, prokinetics, bile acids, statins, and hematopoietic growth factors could also contribute to am

48 It was also demonstrated that these various hematopoietic growth factors, cytokines, and chemokines

49 in response to a number of stimuli including hematopoietic growth factors, cytotoxic agents, and cert

50 403) into normal mouse bone marrow generates hematopoietic growth factor-dependent cell lines frozen

51 retinoic acid receptor was used to establish hematopoietic growth factor-dependent, lympho-myeloid pr

52 The hematopoietic growth factor erythropoietin (Epo) initiat

53 The hematopoietic growth factor erythropoietin (Epo) trigger

54 em increasingly treated with the recombinant hematopoietic growth factor erythropoietin.

55 em increasingly treated with the recombinant hematopoietic growth factor erythropoietin.

56 advanced cancer patients with Flt3 ligand, a hematopoietic growth factor, expanded DCs 20-fold in viv

57 O) is a recently characterized member of the hematopoietic growth factor family that serves as the pr

58 matopoietic progenitors, serum levels of the hematopoietic growth factor Flt3 ligand were dramaticall

59 ents that might influence infection outcome (hematopoietic growth factors, fluconazole, graft-versus-

60 atic allografts from donors treated with the hematopoietic growth factor fms-like tyrosine kinase 3 l

61 row cells expressing p230 required exogenous hematopoietic growth factors for optimal growth, whereas

62 nonanemic low/intermediate-1 IPSS (n = 123), hematopoietic growth factors for patients with anemic lo

63 paB, which results in increased secretion of hematopoietic growth factor G-CSF.

64 gy, cell surface phenotype, or expression of hematopoietic growth factor genes.

65 The hematopoietic growth factors granulocyte colony-stimulat

66 ntly been completed evaluating the effect of hematopoietic growth factors (granulocyte-macrophage col

67 human myeloid differentiation induced by the hematopoietic growth factor, granulocyte-macrophage colo

68 egulation of this protein in response to the hematopoietic growth factors, granulocyte-macrophage col

69 The availability of hematopoietic growth factors has also led to more effect

70 The introduction of hematopoietic growth factors has been a major advancemen

71 Hematopoietic growth factors have made it possible to co

72 Hematopoietic growth factors have played a major role in

73 Hematopoietic growth factors have shown clinical benefit

74 Hematopoietic growth factors (HGF) mobilize potential to

75 RA alone or SCF in combination with 15 other hematopoietic growth factors (HGF) tested.

76 Hematopoietic growth factors (HGFs) stimulate growth, di

77 (PHSCs) requires ex vivo culture in multiple hematopoietic growth factors (HGFs) to promote cell divi

78 creased self-renewal capacity in response to hematopoietic growth factors (HGFs).

79 ectin domain family member 11A [CLEC11A]), a hematopoietic growth factor important for development of

80 onate, which is regulated by an early acting hematopoietic growth factor important for the growth and

81 icle reviews the clinical use of old and new hematopoietic growth factors in acquired and inherited b

82 on the patterns and correlates of the use of hematopoietic growth factors in community-dwelling elder

83 The role of long-acting hematopoietic growth factors in facilitating every-2-wee

84 trated by the heightened growth responses to hematopoietic growth factors in hematopoietic cells of m

85 The role of hematopoietic growth factors in lineage commitment and d

86 ransgenic mouse despite normal expression of hematopoietic growth factors in the BM.

87 ss, medical costs, and cost effectiveness of hematopoietic growth factors in the community.

88 This article explores the use of hematopoietic growth factors in the older cancer patient

89 ry patterns of proliferation in a mixture of hematopoietic growth factors in the presence of differen

90 cellulose cultures and treated with selected hematopoietic growth factors in the presence or absence

91 actice guidelines, and practice patterns for hematopoietic growth factors in the supportive care of c

92 (P = 0.57); however, more patients received hematopoietic growth factors in the valganciclovir group

93 C do not proliferate in response to multiple hematopoietic growth factors in vitro and do not radiopr

94 ind and directly regulate the bioactivity of hematopoietic growth factors including interleukin-7 (IL

95 here was an increase in the mRNA for several hematopoietic growth factors including macrophage colony

96 ere is now good evidence that treatment with hematopoietic growth factors, including granulocyte colo

97 ling induced by engineered Notch ligands and hematopoietic growth factors influences hematopoietic st

98 rum-free cultures containing fibronectin and hematopoietic growth factors inhibited myeloid different

99 We show that the hematopoietic growth factor interleukin (IL)3, maintaine

100 ntibody (mAb), cobra venom factor (CVF), pig hematopoietic growth factors (interleukin-3 (pIL3) and s

101 ontaining medium in the presence of multiple hematopoietic growth factors (interleukin-6, stem cell f

102 ion of DNA plasmids encoding cytokine and/or hematopoietic growth factors, interleukin-2 (IL-2), IL-1

103 t production of certain stromal cell-derived hematopoietic growth factors is deficient as a consequen

104 IL-9, a hematopoietic growth factor, is considered to be a media

105 rt by the production of stromal cell-derived hematopoietic growth factors, is impaired.

106 Hematopoietic growth factors mediate the survival and pr

107 Hematopoietic growth factors mediate their effects on st

108 ting a potential non-hematopoietic effect of hematopoietic growth factors on iron absorption by the g

109 h high-risk aggressive lymphoma by utilizing hematopoietic growth factors or autologous peripheral bl

110 her platelet counts suggest viral effects on hematopoietic growth factors or cytokines.

111 nditions and multipotent cells, mobilized by hematopoietic growth factors or emerging during parasiti

112 ormed cells exhibited complete dependency on hematopoietic growth factors, particularly GM-CSF and IL

113 bstantial geographic variation in the use of hematopoietic growth factors, ranging from 10.6% in Seat

114 in 1 transgene by expressing the nonlymphoid hematopoietic growth factor receptor c-MPL (myeloprolife

115 Normal expression of the hematopoietic growth factor receptor FLT3 (STK-1@Flk2) i

116 Interleukin-3 (IL-3) is a hematopoietic growth factor receptor which stimulates th

117 important factors for regulating a critical hematopoietic growth factor receptor, the M-CSF receptor

118 ively activating point mutations reported in hematopoietic growth factor receptors in patients with a

119 timulating factor receptor and several other hematopoietic growth factor receptors induce the tyrosin

120 nstream signaling events after activation of hematopoietic growth factor receptors.

121 after ex vivo culture in the presence of the hematopoietic growth factors recombinant murine stem cel

122 Prophylactic hematopoietic growth factor (recombinant human granulocy

123 The hematopoietic growth factors regulating these processes

124 Recombinant hematopoietic growth factors represent another therapeut

125 Mpl ligand is the hematopoietic growth factor responsible for regulating t

126 Stimulation of human hematopoietic growth factor responsive cell lines with s

127 cells isolated in vitro responded poorly to hematopoietic growth factors, resulting in an up to 11-f

128 In this report, involvement of Bcl-3 in hematopoietic growth factor-stimulated erythroid prolife

129 cyte-macrophage colony-stimulating factor, a hematopoietic growth factor, stimulates cells of the int

130 Several hematopoietic growth factors such as G-CSF, GM-CSF, and

131 es the possibility that excess expression of hematopoietic growth factors such as IL-3 and GM-CSF may

132 nous IFN-gamma affects the responsiveness to hematopoietic growth factors such as SCF in vitro, our r

133 ogeneic feeder cell layer, or IL-2 and other hematopoietic growth factors such as the c-kit ligand (K

134 compounds affected SCF synergism with other hematopoietic growth factors, such as interleukin-3 or g

135 gressive postremission therapy or the use of hematopoietic growth factor support does not appear to i

136 targeted antibiotic therapy or prophylactic hematopoietic growth factor support.

137 To exploit hematopoietic growth factor synergy, we have sought to c

138 Treatment with Flt3 ligand, a hematopoietic growth factor that dramatically expands th

139 Flt3 ligand (FL) is a hematopoietic growth factor that induces proliferation a

140 Stem cell factor (SCF) is a hematopoietic growth factor that interacts with the rece

141 Colony-stimulating factor-1 (CSF-1) is a hematopoietic growth factor that is released by osteobla

142 phage colony-stimulating factor (M-CSF) is a hematopoietic growth factor that is responsible for the

143 ocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor that is widely used to treat

144 FLT3 ligand is a hematopoietic growth factor that plays a key role in gro

145 Thrombopoietin is a hematopoietic growth factor that regulates the productio

146 Thrombopoietin (TPO) is a hematopoietic growth factor that stimulates megakaryocyt

147 Thrombopoietin is a hematopoietic growth factor that stimulates megakaryopoi

148 Mpl ligands are a family of closely related hematopoietic growth factors that bind to the thrombopoi

149 actors including VEGF, bFGF, IL-8, PDGF, and hematopoietic growth factors that promote endothelial ce

150 ctor (SLF) acts synergistically with various hematopoietic growth factors that use the Jak-Stat pathw

151 When cultured on semisolid media with hematopoietic growth factors, these hematopoietic precur

152 rapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic a

153 stem cells and retrovirus transduction using hematopoietic growth factors to introduce a reporter gen

154 Recombinant hematopoietic growth factors were introduced into clinic

155 Hematopoietic growth factors were not allowed.

156 Prophylactic hematopoietic growth factors were not permitted.

157 Hematopoietic growth factors were not routinely used.

158 Prophylactic hematopoietic growth factors were not used.

159 Hematopoietic growth factors were used in 38% of episode

160 ogenitor cell mobilization is the ability of hematopoietic growth factors with distinct cellular targ

161 ulocyte colony-stimulating factor (G-CSF), a hematopoietic growth factor, with or without dexamethaso